Tumori Journal Abstract Book - October 2020 - 104

104

Tumori Journal 106(2S)

Materials and methods: This study evaluated 717 consecutive luminal MBC pts treated from 2008 to 2020 at the
Cancer Centre of Aviano and the Oncology Department of
Udine, Italy. Differences in terms of overall survival (OS),
progression-free survival (PFS1 and PFS2), and post-progression survival (PPS) were tested by log-rank test and represented by Kaplan-Meier survival curves. The attrition rate
(AR) between 1° and 2°L was calculated. A Cox regression
model was implemented to identify prognostic factors.
Results: At 1°L, pts were treated with ET (49%), chemotherapy (CT) (32%) and ET-CDKi (19%), while 33%
received ET, 33% CT and 9% ET-CDKi at 2°L. AR was
10% for the whole cohort, 7% for CT, 8% for ET and 17%
for ET-CDKi. By multivariate analysis, including potential
confounders, 1°L ET-CDK4/6i showed a better median
PFS1 and OS (Table 1). Moreover, 2°L ET-CDK4/6i

improved median PFS2 compared to ET and CT. Notably,
1°L ET-CDKi resulted in higher median PFS than 2°L use
(22 months vs 12). Intriguingly, 1°L ET-CDK4/6i is associated with worse median PPS compared to CT and ET.
Secondarily, treatment strategies were analysed: 1°L
ET-CDK4/6i followed by CT had worse OS compared to
1°L ET-CDK4/6i followed by ET (Table 1). Notably, none
of baseline characteristics at 2°L, including fast-progressive disease, influenced 2°L treatment choice (ET vs. CT)
after ET-CDKi.
Conclusions: Our real-world data demonstrated that
ET-CDKi represents the best option for 1°L luminal MBC
compared to ET and CT. Also, the present study pointed
out that 2°L ET, potentially combined with other targeted
molecules, could be a feasible option after CDK4/6i failure, postponing CT on later lines.

Table 1. Survival Outcomes.
PFS
1°L
ET-CDKi
ET vs ET-CDKi
CT vs ET-CDKi
2°L
ET-CDKi
ET vs ET-CDKi
CT vs ET-CDKi
2°L after CDKi
ET
CT

HR; 95% CI; P

Median (mo)

HR; 95% CI; P

Median (mo)

1
1.93; 1.37-2.73; <0.001
1.93; 1.35-2.74; <0.001

22
14
12

1
1.40; 0.86-2.28; 0.17
1.25; 0.75-2.03; 0.40

Not reached (NR)
27
49

1
1.72; 1.17-2.51; 0.005
1.86; 1.28-2.72; 0.001

12
7
6

E11
Population-based testing
for Hereditary Breast and
Ovarian Cancer in a cohort of
1,346 patients from Southern
Italy (Sicily): can historical
background affect genetics?
Fanale D.1, Incorvaia L.2, Bono M.1, Calò V.1, Cancelliere D.1, Fiorino
A.1, Barraco N.1, Brando C.1, Perez A.1, Corsini L.R.1, Madonia G.1,
Ricciardi M.R.1, Cucinella A.1, Lisanti M.C.1, Filorizzo C.1, Maria
Tomasello L.M.1, Gristina V.1, Cusenza S.1, Bazan V.2, Russo A.1
1
Department of Surgical, Oncological and Oral Sciences, Section of Medical
Oncology, University of Palermo, Palermo; 2Section of Medical Oncology,
Department of Biomedicine, Neuroscience and Advanced Diagnostics
(Bi.N.D.), University of Palermo, Palermo

Background: Recent advances in detection of germline
pathogenic variants (PVs) in BRCA1/2 genes allowed a
deeper understanding of the BRCA-related cancer risk.
Several studies showed a significant heterogeneity in the

1
5.04;1.12-22.7; 0.035

NR
20

prevalence of PVs across different populations. The development of new population-based genetic approaches may
help to detect the 50% more BRCA-carriers than those
identified by conventional clinical and familial criteria, as
already shown in other studies. Because little is known
about this in Sicilian population, our study was aimed at
investigating the prevalence and geographic distribution of
inherited BRCA1/2 PVs in families from this specific geographical area of Southern Italy.
Patients and methods: We retrospectively collected and
analyzed all clinical information of 1,346 hereditary breast
and/or ovarian cancer patients genetically tested for germline BRCA1/2 PVs by Next-Generation Sequencing
analysis at University Hospital Policlinico "P. Giaccone"
of Palermo from January 1999 to October 2019.
Results: 102 BRCA-positive subjects carried a BRCA1 PV,
96 harboured a BRCA2 PV, and 2 showed simultaneous presence of PVs in both genes. The BRCA1-5083del19 founder
variant is resulted to be the most widespread PV in the Sicilian
population, together with other two PVs named BRCA21466delT and BRCA1-633delC. Interestingly, several

Tumori Journal Abstract Book - October 2020

Table of Contents for the Digital Edition of Tumori Journal Abstract Book - October 2020